RIPK1

Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

Retrieved on: 
Monday, January 8, 2024
CSF, Lysosomal storage disease, Cerebrospinal fluid, Risk, Sanfilippo syndrome, Amyloid, BBB, UC, Sanfilippo, Manuscript, ETV, ALS, OTV, SNCA, IDS, Asos, Conference, Cognition, RIPK1, Fluid mechanics, Neuroinflammation, Premedication, Glycogen storage disease, Amyloid beta, SGSH, Therapy, COMPASS, Traffic barrier, Hunting, N-sulfoglucosamine sulfohydrolase, Hunter syndrome, ISR, NewCo, Amyloid-related imaging abnormalities, Inflammation, CNS, Neurodegenerative disease, Takeda, Biomarker, Alpha-synuclein, K2, Biology, DSM-IV codes, LUMA, Brain, MPS, Investigational New Drug, PTV, ARIA, Nerve, AFL, Pathology, MPS II, Interim, BioRxiv, Plaque, MAPT, LRRK2, Elevator mechanic

The global Phase 2/3 COMPASS study continues to recruit up to 54 participants with neuronopathic and non-neuronopathic MPS II.

Key Points: 
  • The global Phase 2/3 COMPASS study continues to recruit up to 54 participants with neuronopathic and non-neuronopathic MPS II.
  • Upon completion of the ongoing Phase 1/2 study, and together with data from COMPASS, this combined data package is intended to support registration.
  • Increased RIPK1 activity in the CNS is hypothesized to drive neuroinflammation and cell necroptosis and to contribute to neurodegeneration.
  • Denali will maintain ownership of and continue to advance its current portfolio of clinical stage small molecule programs.

Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
Tuesday, November 7, 2023
Neurofilament light polypeptide, MPS II, CLE, Biomarker, Therapy, MS, BioRxiv, ETV, Ulcerative colitis, BBB, ALS, PTV, ATV, ROFN, Definitive, Traffic barrier, Hunter syndrome, Phase 10, Denali, MPS, Antibody, Biology, Safety, Patient, AFL, Plaque, Fluid mechanics, ASO, ARIA, RIPK1, Asos, Research, Cerebrospinal fluid, ISR, SGSH, DSM-IV codes, Nerve, Brain, Society, Total, OTV, N-sulfoglucosamine sulfohydrolase, Hunting, LUMA, Glycogen storage disease, Manuscript, UC, CSF, Amyloid-related imaging abnormalities, Takeda, COMPASS, Pathology, CNS, Sanfilippo, Neuroinflammation, Collaboration, Multiple sclerosis, Sanfilippo syndrome, IDS, Cognition, Mutation, SAN, Pharmaceutical industry, Medical imaging, Fine chemical, Cryptocurrency, Biogen, LRRK2, Metabolism, Sanofi

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the third quarter ended September 30, 2023, and provided business highlights.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the third quarter ended September 30, 2023, and provided business highlights.
  • Denali has selected five ASO targets for further development and is focused on advancing two OTV candidates towards clinical development.
  • 2023 Guidance on Operating Expenses:
    Cash, cash equivalents, and marketable securities were approximately $1.12 billion as of September 30, 2023.
  • General and administrative expenses were $25.3 million and $23.3 million for the three months ended September 30, 2023 and 2022, respectively.

Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Retrieved on: 
Monday, February 27, 2023
Hearing, Asos, IND, Lupus, Biomarker, PTV, Biology, Therapy, Neuroinflammation, ETV, Multiple sclerosis, Hunter syndrome, ALS, Safety, MS, TREM2, Takeda, Standard of care, DSM-IV codes, Patient, ATV, SGSH, IDS, CLE, Hospital, ISR, Parkinson's disease, COMPASS, RIPK1, LRRK2, Type 3 submergence transport vehicle, MPS II, CSF, Brain, Massachusetts General Hospital, Bank, BBB, CNS, MGH, Glycogen storage disease, MPS, The Annual, International Symposium on Endovascular Therapy, Traffic barrier, Sanfilippo syndrome, Bank of America, Sanfilippo, N-sulfoglucosamine sulfohydrolase, LUMA, ASO, SAN, Conference, Hunting, OTV, Pharmaceutical industry, Medical imaging, Medical device, Vaccine, Fine chemical, Cryptocurrency, Biogen, Sanofi

In February 2023, at the WORLDSymposiumTM, Denali reported additional interim data from the open-label, single-arm Phase 1/2 study of DNL310.

Key Points: 
  • In February 2023, at the WORLDSymposiumTM, Denali reported additional interim data from the open-label, single-arm Phase 1/2 study of DNL310.
  • The Phase 2/3 COMPASS study continues to enroll up to 54 participants with MPS II with and without neuronopathic disease.
  • In October 2022, Denali raised net proceeds of approximately $296.2 million through a public offering of its common stock.
  • 2023 Guidance on Operating Expenses:
    Cash, cash equivalents, and marketable securities were $1.34 billion as of December 31, 2022.

Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by Sanofi

Retrieved on: 
Wednesday, January 25, 2023
CNS, Traffic barrier, RIPK1, Multiple sclerosis, Denali, Sclerosis, Neurodegeneration, Central nervous system, HIV disease progression rates, SAN, ALS, Neurology, Glycogen storage disease, Cell death, Therapy, Inflammation, Pharmaceutical industry, Sanofi

SAR443820 is a central nervous system (CNS)-penetrant investigational small molecule inhibitor of RIPK1.

Key Points: 
  • SAR443820 is a central nervous system (CNS)-penetrant investigational small molecule inhibitor of RIPK1.
  • “Multiple sclerosis is a chronic and disabling, inflammation-mediated neurodegenerative disease with limited treatment options that target disease progression1,” said Nazem Atassi, M.D., Global Head of Early Neurology Development at Sanofi.
  • “RIPK1 inhibition with SAR443820 is a novel therapeutic approach that may reduce inflammation and cell death associated with disease progression in multiple sclerosis.
  • “We look forward to collaborating with Sanofi as we aim to make a meaningful difference for individuals living with neurodegenerative diseases by delivering novel treatment options.”

Denali Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

Retrieved on: 
Thursday, November 3, 2022
PTV, Private Securities Litigation Reform Act, Biogen, Prisoner transport vehicle, LRRK2, CNS, CSF, U.S. Securities and Exchange Commission, COMPASS, Collaboration, SEC, Neurodegeneration, Program, Glycogen storage disease, SAN, GLOBE, Total, Amyotrophic lateral sclerosis, Toxic shock syndrome, Tax, Hunter syndrome, BBB, LUMA, Forward-looking statement, Ulcerative colitis, Environment, Security (finance), Disease, Patient, Cerebrospinal fluid, Multiple sclerosis, COVID-19, HIV disease progression rates, Parkinson's disease, International Symposium on Endovascular Therapy, Blood, The Annual, Caregiver, Penetrance, RIPK1, Industry, Traffic barrier, Biomarker, Conference, Two-phase electric power, Therapy, Nasdaq, Lupus, ATV, Credit Suisse, Risk, ETV, Pharmaceutical industry, Air cargo, Takeda, ALS, Genentech, Sanofi

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial results for the third quarter ended September 30, 2022, and provided business highlights.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial results for the third quarter ended September 30, 2022, and provided business highlights.
  • In November 2022, Denali announced interim results from Part A of the Phase 1/2 study evaluating TAK-594/DNL593 (PTV:PGRN) in healthy subjects.
  • In October 2022, Denali raised net proceeds of approximately $296.2 million through a public offering of its common stock.
  • The forward-looking statements in this press release are based on information available to Denali as of the date hereof.

Denali Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

Retrieved on: 
Monday, August 8, 2022
U.S. Securities and Exchange Commission, GLOBE, SEC, Security (finance), Research, Clinical trial, Patient, CTA, Collaboration, Neurodegeneration, Ulcerative colitis, Toxic shock syndrome, Program, CSF, Travel, Risk, Industry, CNS, Private Securities Litigation Reform Act, RIPK1, Environment, LRRK2, SAN, Tax, Safety, COMPASS, Nasdaq, Conference, Traffic barrier, EIF2B, MPS, Parkinson's disease, Interim, Forward-looking statement, LUMA, Lupus, Biogen, ATV, Report of the 1st Annual Symposium on Relaxed Improvisation, Therapy, COVID-19, Morgan Stanley, Science Translational Medicine, Multiple sclerosis, Hunter syndrome, Biomarker, MPS II, PTV, BBB, Citigroup, ETV, Alzheimer's disease, Insurance, Renewable energy, Pharmaceutical industry, Medical device, Medicine, Health insurance, Tutoring, Sanofi, Metabolism, Takeda, ALS

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial results for the second quarter ended June 30, 2022, and provided business highlights.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial results for the second quarter ended June 30, 2022, and provided business highlights.
  • Denali plans to present data from the ongoing Phase 1b study in ALS in the second half of 2022.
  • Pending initial clinical data, Denali expects to begin dosing participants with FTD-GRN in the second half of 2022.
  • Denali received a $40 million milestone payment from Sanofi in the second quarter related to initiation of the Phase 2 HIMALAYA study.

Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in ALS by Sanofi

Retrieved on: 
Monday, May 2, 2022
COVID-19, Amyotrophic lateral sclerosis, TNF, U.S. Securities and Exchange Commission, Communication, Forward-looking statement, BBB, Private Securities Litigation Reform Act, Brain, Ulcerative colitis, NASDAQ, Pharmacokinetics, GLOBE, CNS, MS, Biomarker, Safety, Food, Patient, Security (finance), Partnership, Review, Neurodegeneration, Clinical trial, Program, Risk, FDA, Inflammation, Therapy, Industry, Lupus, Adult, Fast Track, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cell death, Disease, Traffic barrier, SEC, RIPK1, Technology, SAN, Toxic epidermal necrolysis, ALS, Central nervous system, Multiple sclerosis, Pharmaceutical industry, Medical device, Sanofi

The initiation of this Phase 2 study marks a significant milestone in the SAR443820 development program and our RIPK1 inhibitor collaboration with Sanofi, said Denalis Chief Medical Officer, Carole Ho, M.D.

Key Points: 
  • The initiation of this Phase 2 study marks a significant milestone in the SAR443820 development program and our RIPK1 inhibitor collaboration with Sanofi, said Denalis Chief Medical Officer, Carole Ho, M.D.
  • Denali is committed to collaborating with the ALS community as we work toward a unified goal of developing potentially life-saving therapeutics for people living with ALS.
  • Sanofi leads Phase 1 and Phase 2 development of SAR443820 for ALS and MS and leads co-development of SAR443820 with Denali in Phase 3 clinical trials for ALS, MS and Alzheimers disease.
  • Sanofi is also conducting a Phase 2 clinical trial of the peripherally restricted RIPK1 inhibitor SAR443122 (eclitasertib) (DNL758) in cutaneous lupus erythematosus and plans to initiate a Phase 2 clinical trial in ulcerative colitis.

Global RIPK1 inhibitor Market Research Report 2022: Comprehensive Insights About 10+ Companies and 12+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 10, 2022
Pharmaceutical, Health, Clinical Trials, Other Health, RIP1, Clinical trial, Cell death, Inflammation, Rigel, Sanofi, Therapy, Survival, Degenerative disease, Neurodegeneration, Tissue, TNF, Mergers and acquisitions, Ulcerative colitis, NDA, News, Acquisition, Discovery, Patient, Technology, Immunity, Severe acute respiratory syndrome coronavirus 2, Eli Lilly, Pharmaceutical industry, RIPK1

The publisher's, "RIPK1 inhibitors - Pipeline Insight, 2022," report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in RIPK1 inhibitors pipeline landscape.

Key Points: 
  • The publisher's, "RIPK1 inhibitors - Pipeline Insight, 2022," report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in RIPK1 inhibitors pipeline landscape.
  • "RIPK1 inhibitors - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication.
  • A detailed picture of the RIPK1 inhibitors pipeline landscape is provided which includes the disease overview and RIPK1 inhibitors treatment guidelines.
  • The assessment part of the report embraces, in depth RIPK1 inhibitors commercial assessment and clinical assessment of the pipeline products under development.

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2021 Financial Results and Business Update

Retrieved on: 
Tuesday, February 22, 2022
Degenerative disease, Webcast, Waiha, NIH, IRAK, COVID-19, Company, Investor relations, United Kingdom, Disease, Daiichi Sankyo, Tablet, ASA, Fostamatinib, Adult, Eli Lilly and Company, RIPK1, Imperial College London, FDA, Cancer, Nasdaq, SAN, Rigel, Patient, Research, SYK, Pharmaceutical industry

(Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2021 financial results after market close on Tuesday, March 1, 2022.Rigel senior management will follow the announcement with a live conference call and webcast at 4:30pm Eastern Time (1:30pm Pacific Time) to discuss the financial results and give an update on the business.

Key Points: 
  • (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2021 financial results after market close on Tuesday, March 1, 2022.Rigel senior management will follow the announcement with a live conference call and webcast at 4:30pm Eastern Time (1:30pm Pacific Time) to discuss the financial results and give an update on the business.
  • Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to developing and commercializing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer, and rare immune diseases.
  • In addition, Rigel has product candidates in development with partners BerGenBio ASA and Daiichi Sankyo.
  • 1The product for this use or indication is investigational and has not been proven safe or effective by any regulatory authority.

Rigel to Present at the J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 10, 2022
Daiichi Sankyo, Patient, Research, NIH, Conference, Rigel, SAN, Investor relations, Tablet, COVID-19, Adult, IRAK, Disease, RIPK1, Fostamatinib, Nasdaq, United Kingdom, Company, Degenerative disease, SYK, Cancer, Waiha, ASA, Software, FDA, Imperial College London, Eli Lilly and Company, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the 40th Annual J.P. Morgan Healthcare Conference at 10:30 a.m.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the 40th Annual J.P. Morgan Healthcare Conference at 10:30 a.m.
  • To access the live and subsequently archived webcast, go to the Investor Relations section of the company's website at www.rigel.com .
  • In addition, Rigel has product candidates in development with partners BerGenBio ASA, and Daiichi Sankyo.
  • 1The product for this use or indication is investigational and has not been proven safe or effective by any regulatory authority.